eli lilly retatrutide trials Lilly's triple agonist achieves 16.8% weight loss in phase 3 trial Who got Eli Lilly retatrutide;
Description
Throughout the study, patients metformin and insulin doses were expected to remain stable, except for a dose reduction if they experienced hypoglycemia
Yet in the most recent month, from June to July 2025, AOM semaglutide prescribing increased by 4.9%, the largest one-month gain in first-time AOM semaglutide prescribing in over a year
Adding pharmacological glucagon activation on top of this could theoretically worsen fatigue, dizziness, and brain fog
E.RedlineS.AzarbarzinA.et al (2024)
2016;311(2):H433H444
